Actualités PharmaTher Holdings Ltd - PHRM | Actions Canadian Securities Exchange

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch Delivering psilocybin via microneedle patch unlocks potential for...

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch Focusing on...

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products Leading U.S.-based CDMO to manufacture...

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome Achieving its second FDA orphan drug...

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund TORONTO, September 21, 2021 -- InvestorsHub...

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 10 clinical sites...

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis Focusing on becoming a global leader in...

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation Strengthens position to...

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression Potential...

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease TORONTO, May 25, 2021...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease TORONTO, May 17, 2021 -- InvestorsHub NewsWire...

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..Cont

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with...

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of...

PharmaTher Provides Update on Psychedelic Product Programs

PharmaTher Provides Update on Psychedelic Product Programs TORONTO, Canada -- April 15, 2021 -- InvestorsHub NewsWire -- PharmaTher...

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....Cont

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PharmaTher Holdings Ltd (PHRM)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHRM Actualités

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..Cont

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial

PharmaTher Provides Update on Psychedelic Product Programs

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....Cont

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

PharmaTher Holdings Ltd (PHRM) Actualités

PharmaTher Holdings Ltd (PHRM)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHRM Actualités

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig's Disease

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson's Disease

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics..Cont

PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial

PharmaTher Provides Update on Psychedelic Product Programs

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou....Cont

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application